Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Atorvastatin is a small molecule drug in the class of HMG-CoA reductase inhibitors (statins) used to lower cholesterol and triglyceride levels in the blood. It works by reversibly inhibiting HMG-CoA reductase—the rate-limiting enzyme in cholesterol biosynthesis—thereby reducing total cholesterol (especially LDL-C), apolipoprotein B (apo B), non-HDL-C and triglycerides while increasing HDL-C. Lowering these lipid levels reduces the risk of atherosclerosis and cardiovascular events such as heart attack and stroke. Atorvastatin is indicated for primary and secondary prevention of cardiovascular disease including myocardial infarction and stroke; it is also used to treat various forms of hypercholesterolemia including familial heterozygous hypercholesterolemia in children aged 10–17 years[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on atorvastatin.